Fusen Pharmaceutical Company Limited (FUSEN PHARM) filed its Monthly Return for the period ended 31 May 2026, confirming a stable capital structure and full compliance with Hong Kong’s public-float rules. Key disclosures are as follows:

• Authorised capital unchanged: The company maintained 2.00 billion ordinary shares with a par value of HKD 0.01, representing authorised share capital of HKD 20.00 million. No increases or reductions occurred during May.

• Issued share capital steady: Issued shares (excluding treasury shares) remained at 739.30 million. No new shares were issued, and no treasury shares were created, cancelled or transferred.

• Public-float requirement met: As at 31 May 2026, the company confirmed compliance with the Main Board’s minimum 25% public-float threshold.

• Share-based incentives: Under the Share Option Scheme adopted on 14 June 2018, 16.00 million options granted on 19 July 2019 (exercise price HKD 3.098; exercisable from 19 October 2019 to 13 June 2028) remained outstanding at month-end. No options were exercised in May, leaving potential issuance capacity for up to 16.00 million shares. The scheme’s aggregate mandate allows for up to 80.00 million shares.

• No other equity-linked instruments: The filing reports no warrants, convertible securities, additional option arrangements or other movements in issued or treasury shares during the month.

Overall, FUSEN PHARM’s share capital and share count were unchanged in May 2026, with zero funds raised from equity exercises. The company’s capital position and compliance status remain intact heading into June.